Effect of 7 and 13-Valent Pneumococcal Conjugate Vaccines Different Number of Doses for Pneumonia Control in 2008 and 2010 Birth Cohort Children

DOI: 10.4236/wjv.2015.51005   PDF   HTML   XML   5,868 Downloads   6,421 Views   Citations


The 7-valent pneumococcal conjugate vaccine (PCV) was introduced in Uruguay in March 2008. In April 2010, it was replaced by PCV13. Surveillance of both vaccines was performed on hospitalized children with consolidated pneumonia. The effect of different number of vaccine doses was evaluated in 2008 and 2010 birth cohorts vaccinated with PCV7 and PCV13 respectively. The study aims to estimate the effects of PCV7 and PCV13 different number of doses on consolidated pneumonia, through the study of hospitalized children from 2008 and 2010 birth cohorts. Vaccination records of every child were available providing precise vaccination data; therefore a new approach was used to estimate PCVs effect. Incidence rate was calculated for each year of the study and for the different number of vaccine doses used each year. Exposure was calculated as person per year and rate ratio values determined the decrease of consolidated pneumonias. This decrease in percentage was estimated as the difference between the incidence with no vaccine and the incidence of every one of the doses. Incidence rate ratio revealed significant values for the three vaccine doses of PCVs for both cohorts. Upon comparing incidences, significant reduction percentages of consolidated pneumonia admissions were found. The reduction percentage of consolidated pneumonia for fully vaccinated (3 doses) patients was 69.3% and 84.6 % for PCV7 and PCV13, respectively. These results confirm that PCV7 and PCV13 are highly effective for reducing pediatric hospitalizations due to consolidated pneumonia, as reported by other national publications and demonstrated by international researchers.

Share and Cite:

Hortal, M. , Meny, M. , Estevan, M. , Arrieta, F. and Laurani, H. (2015) Effect of 7 and 13-Valent Pneumococcal Conjugate Vaccines Different Number of Doses for Pneumonia Control in 2008 and 2010 Birth Cohort Children. World Journal of Vaccines, 5, 37-42. doi: 10.4236/wjv.2015.51005.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Hortal, M., Estevan, M., Laurani, H., Iraola, I. and Meny, M., Paysandú/Salto Study Group (2012) Hospitalized Children with Pneumonia in Uruguay: Pre and Post Introduction of 7 and 13-Valent Pneumococcal Conjugated Vaccines into the National Immunization Program. Vaccine, 33, 4934-4938.
[2] Hortal, M., Estevan, M., Meny, M., Iraola, I. and Laurani, H. (2014) Impact of Pneumococcal Conjugate Vaccine on the Incidence of Pneumonia in Hospitalized Children after Five Years of Its Introduction in Uruguay. PLoS One, 9, e98567. www.plosone.org
[3] Ronveaux, O., Arrieta, F., Curto, S., Laurani, H. and Danovaro-Holliday, M.C. (2006) Assessment of the Quality of Immunization Data Produced by the National Individual Registration System in Uruguay, 2006. Revista Panamericana de Salud Pública, 26, 153-160.
[4] (2001) World Health Organization Pneumonia Vaccine Trial Investigator’s Group, Standardization of Interpretation of Chest Radiographs for the Diagnosis of Pneumonia in Children, World Health Organization Geneva.
[5] Pita Fernández, S., Pértigas Díaz, S. and Valdés Canedo, F. (2013) Medidas de frecuencia de enfermedad. Madrid: Fisterra, Disponible en.
[6] Prentice, R.L. (1986) A Case-Cohort Design for Epidemiologic Cohort Studies and Disease Prevention Trials. Biometrika, 73, 1-11.
[7] Rothman, K.J. (1986) Modern Epidemiology. 5. Measures of Disease Frequency, 23-34. Little, Brown and Company. Boston/Toronto.
[8] O’Brien, K.K., Goldblatt, D. and Witney, C.G. (2014). Why Do We Need a Systematic Review of Pneumococcal Conjugate Vaccine Dosing Schedules? Pediatric Infectious Disease Journal, 33, S107-S108.
[9] Pirez, M.C., Algorta, G., Sobrero, H., Varela, A., Giachetto, G. and Montano, A. (2011) Impact of Pneumococcal Universal Vaccination of Hospitalizations for Pneumonia and Meningitis in Children in Montevideo, Uruguay. Pediatric Infectious Disease Journal, 30, 669-674.
[10] Picon, T., Alonso, L., Garcia Garrabot, G., Speranza, N., Casas, M., Arrieta, F., Camou, T., Rosa, R., De Oliveira, L.H., Verani, J.R. (2013) Effectiveness of the 7-Valent Pneumococcal Conjugate Vaccine against Vaccine-Type Invasive Disease among Children in Uruguay: An Evaluation Using the Existing Data. Vaccine, 315, C105-C113.
[11] Huebner, R.E., Mbelle, N., Forrest, B., Madore, D.V. and Klugman, K.P. (2002) Immunogenicity after One, Two or Three Doses and Impact on the Antibody Response to Coadministered Antigens of a Nonavalent Pneumococcal Conjugate Vaccine in Infants of Sweto, South Africa. Pediatric Infectious Disease Journal, 21, 1004-1007.
[12] De Wals, P., Robin, E., Fortin, E., Thibeault, R., Ouakki, M. and Douville-Frader, M. (2008) Pneumonia after Implementation of Pneumococcal Conjugate Vaccine Program in the Province of Quebec, Canada. Pediatric Infectious Disease Journal, 27, 963-968.
[13] Verani, J.R., Givon-Lavi, R., Whitney, C.G., Greenberg, D. and Dagan, R. (2014) Effectiveness of Pneumococcal Conjugate Vaccine against Pneumonia in Israel. Pneumonia, S3, 278.
[14] Esposito, S., Lizioli, A., Lastrico, A., Begliatti, E., Rognoni, A., Tagliabue, C., Cesari, L., Carreri, V. and Principi, N. (2007) Impact on Respiratory Tract Infections If Heptavalent Pneumococcal Conjugate Vaccine Administred at 3, 5 and 11 Months of Age. Respiratory Research, 8, 12.
[15] Ansaldi, E., Sticchi, L., Durando, P., Begliatti, E., Rognoni, A., Tagliabue, C., Crovari, P. and Icardi, G. (2008) Decline in Pneumonia and Acute Otitis Media after the Introduction of Childhood Pneumococcal Vaccination in Liguria, Italy. Journal of International Medical Research, 26, 1255-1260.

comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.